Despite the recent development of new antiepilepsy drugs, a significant number of children are still unable to achieve seizure freedom without side effects. Understanding the factors behind individual variability in antiepilepsy drug tolerability and dose response and incorporating these factors into a treatment plan would represent an important advance in epilepsy pharmacotherapy. A more thorough understanding of the epileptogenic process may allow clinicians to select antiepilepsy drugs that interrupt or modify various steps in the epileptogenic progression (ie, disease modification). Additionally, advances in the understanding of human genetics may allow for selection of antiepilepsy drugs and dosage regimens based on a patient's clinical characteristics and genotype (ie, pharmacogenetics). This article focuses on these two areas of potential improvement in the medical treatment of patients with epilepsy. Such methods of tailoring antiepilepsy drug therapy would be preferable to the trial-and-error system that is currently used. (J Child Neurol 2001;17:S85—S93).
References
1.
Temkin NR, Jarell AD, Anderson GD: Antiepileptogenic agents: How close are we?Drugs2001;61:1045—1055.
2.
Perucca E.: Principles of drug treatment, in Shorvon S , Fish D, Thomas D (eds): The Treatment of Epilepsy. London, Blackwell Science, 1996, 152—168.
3.
Guberman A., Bruni J.: Essentials of Clinical Epilepsy. Boston, Butterworth-Heinemann, 1999.
4.
Mattson RH, Cramer JA, Collins JF: Prognosis for total control of complex partial and secondarily generalized tonic-clonic seizures. Department of Veterans Affairs Epilepsy Cooperative Studies No. 118 and No. 264 Group. Neurology1996;47:68—76.
Devinsky O.: Patients with refractory seizures. N Engl J Med1999; 340:1565—1570.
7.
Duncan JS: Principles of treatment of patients with chronic active epilepsy, in Shorvon S, Fish D, Thomas D (eds): The Treatment of Epilepsy. London, Blackwell Science, 1996, 177—190.
8.
Hooper WD, Johnson LP: Measurement of anticonvulsants and their metabolites in biological fluids , in Eadie MJ, Vajda FJE (eds): Antiepileptic Drugs Pharmacology and Therapeutics , vol 138. Berlin, Springer, 1999, 172—187.
9.
Pippenger C. , Bastiani R., Schneider R.: Gas chromatographic analysis for anticonvulsant drugs in biologic fluids. Clin Chem1969;15: 582—590.
10.
Johannessen SI : General principles: Methods of determination of antiepileptic drugs, in Levy R, Mattson R, Meldrum B (eds): Antiepileptic Drugs, 4th ed. New York, Raven Press, 1995, 243—270.
11.
Sander J., White H.: Disease modification in epilepsy. Prog NeurolPsychiatr2001;5(Suppl 2):1—12.
12.
Cole AJ: Is epilepsy a progressive disease? The neurobiological consequences of epilepsy . Epilepsia2000;41:S13—S22.
13.
Lipton SA, Rosenberg PA: Excitatory amino acids as a final common pathway for neurologic disorders . N Engl J Med1994;330: 613—622.
14.
Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE: An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia2000;41:S3—S9.
Jensen FE, Holmes GL, Lombroso CT, et al: Age-dependent changes in long-term seizure susceptibility and behavior after hypoxia in rats. Epilepsia1992;33:971—980.
17.
Jensen FE, Blume H., Alvarado S., et al: NBQX blocks acute and late epileptogenic effects of perinatal hypoxia. Epilepsia1995;36: 966—972.
18.
Koh S., Jensen FE: Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Ann Neurol2001;50:366—372.
19.
Pippenger CE, Meng X., Rothner AD, et al: Free radical scavenging enzyme activity profiles in risk assessment of idiosyncratic drug reactions, in Levy RH , Penry JK (eds): Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity . New York, Raven Press, 1991, 75—87.
20.
Warner BB, Wispe JR: Free radical-mediated diseases in pediatrics. Semin Perinatol1992;16:47—57.
21.
Roberfroid M. , Buc Caldron P: Definitions, properties, and reactions of radicals, in Roberfroid M, Buc Calderon P (eds): Free Radicals and Oxidation Phenomena in Biological Systems. New York, Marcel Dekker, 1995, 13—31.
22.
Weber GF, Maertens P., Xiangxiong M., Pippenger CE: Glutathione peroxidase deficiency and childhood seizures. Lancet1991;337: 1443—1444.
23.
Willmore LJ : Post-traumatic epilepsy: Cellular mechanisms and implications for treatment. Epilepsia1990;31:S67—S73.
24.
Krinsky NI: Mechanism of action of biological antioxidants. Proc Soc Exp Biol Med1992;200:248—254.
25.
Frei B., Stocker R., Ames BN: Small molecule antioxidant defenses in human extracellular fluids. Cell Mol Biol1992;5:23—45.
26.
Halliwell B., Gutteridge J.: Free Radicals in Biology and Medicine. Oxford, Oxford University Press, 1999.
27.
Neve J.: Biological functions of selenium, in Neve J, Favier A (eds): Selenium in Medicine and Biology, vol 1. Berlin, de Gruyter, 1989, 97—111.
28.
Mori A., Noda Y., Packer L.: The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res1998;30:153—158.
29.
Noda Y., Mori A., Packer L.: Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus. Res Commun Mol Pathol Pharmacol1999;105:23—33.
30.
Tokumaru J., Ueda Y., Yokoyama H., et al: In vivo evaluation of hippocampal antioxidant ability of zonisamide in rats. Neurochem Res2000;25:1107—1111.
31.
Komatsu M., Hiramatsu M., Willmore LJ: Zonisamide reduces the increase in 8-hydroxy-2'-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats. Epilepsia2000; 41:1091—1094.
32.
Kanthasamy AG, Matsumoto RR, Gunasekar PG, Trunong DD: Excitoprotective effect of felbamate in cultured cortical neurons. Brain Res1995;705:97—104.
33.
Shuaib A., Waqaar T., Ijaz MS, et al: Neuroprotection with felbamate: A 7- and 28-day study in transient forebrain ischemia in gerbils. Brain Res1996 ;727:65—70.
34.
Glauser TA: Idiosyncratic reactions: New methods of identifying high-risk patients. Epilepsia2000;41:S16—S29.
35.
Norton RM: Clinical pharmacogenomics: Applications in pharmaceutical R&D. Drug Discov Today2001;6:180—185.
36.
Nebert DW: Extreme discordant phenotype methodology: An intuitive approach to clinical pharmacogenetics. Eur J Pharmacol2000;410:107—120.
37.
Jacobs MP, Fischbach GD, Davis MR, et al: Future directions for epilepsy research. Neurology2001;57:1536—1542.
38.
Nebert DW: Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?Clin Genet1999;56:247—258.
39.
Vesell ES: Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol2000;40:930—938.
40.
Dodson WE: Pharmacokinetic principles of antiepileptic therapy in children, in Dodson WE, Pellock JM (eds): Pediatric Epilepsy: Diagnosis and Therapy. New York, Demos Publications, 1993 , 231—240.
41.
Eadie M.: Pharmacokinetic principles of drug treatment, in Shorvon S, Fish D, Thomas D (eds): The Treatment of Epilepsy . London, Blackwell Science, 1996, 138—151.
42.
Rowland M., Tozer T.: Clinical Pharmacokinetics: Concepts and Applications. Philadelphia, Lippincott, Williams & Wilkins, 1995.
43.
Pirmohamed M., Kitteringham NR, Park BK: The role of active metabolites in drug toxicity . Drug Saf1994;11:114—144.
44.
Shapiro L., Shear N.: Mechanisms of drug reactions: The metabolic track. Semin Cutan MedSurg1996;15:217—227.
Macdonald RL , Kelly KM: Antiepileptic drug mechanisms of action. Epilepsia1995;36:S2—S12.
47.
Rho JM, Sankar R.: The pharmacologic basis of antiepileptic drug action. Epilepsia1999;40:1471—1483.
48.
Physician Drug & Diagnosis Audit (PDDA).Newton, PA, Scott-Levin, 2001.
49.
Cloyd JC, Remmel RP: Antiepileptic drug pharmacokinetics and interactions: Impact on treatment of epilepsy. Pharmacotherapy2000;20:139S—151S.
50.
Gentest, Website. Available at: http://www.gentest.com . Accessed December 27, 2001.
51.
Evans D.: Cytochrome P450—General features, in Evans D (ed): Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics. Cambridge, Cambridge University Press, 1993, 9—18.
52.
Omiecinski CJ, Remmel RP, Hosagrahara VP: Concise review of the cytochrome P450s and their roles in toxicology. Toxicol Sci1999 ;48:151—156.
53.
Nelson DR, Koymans L., Kamataki T., et al: P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics1996;6:1—42.
54.
Nebert DW, Nelson DR, Coon MJ, et al: The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol1991;10:1—14.
55.
van der Weide J., Steijns LS:Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem1999;36:722—729.
56.
Human Cytochrome P450 (CYP) Allele Nomenclature Committee, website. Available at: http://www.imm.ki.se/cypalleles. Accessed December 27, 2001.
57.
Kitagawa K. , Kunugita N., Kitagawa M., Kawamoto T.:CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem2001;276:17830—17835.
58.
Ariyoshi N. , Sawamura Y., Kamataki T.: A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem Biophys Res Commun2001;281:810—814.
59.
Pitarque M. , von Richter O., Oke B., et al: Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: Impairment of its promoter activity. Biochem Biophys Res Commun2001;284:455—460.
60.
Hadidi H., Zahlsen K., Idle JR, Cholerton S.: A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem Toxicol1997;35:903—907.
61.
Oscarson M. , McLellan RA, Gullsten H., et al: Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population . FEBS Lett1999;448: 105—110.
62.
Nunoya KI, Yokoi T., Kimura K., et al: A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther1999;289:437—442.
63.
Nunoya K., Yokoi T., Takahashi Y., et al: Homologous unequal crossover within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype. J Biochem ( Tokyo) 1999;126:402—427.
64.
Nunoya K., Yokoi T., Kimura K., et al: A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502) . Pharmacogenetics1998;8:239—249.
65.
Oscarson M. , McLellan RA, Gullsten H., et al: Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism . FEBS Lett1999;460:321—327.
66.
Lang T., Klein K., Fischer J., et al: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics2001;11:399—415.
67.
Dai D., Zeldin DC, Blaisdell JA, et al: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics2001;11:597—607.
68.
Rettie AE, Wienkers LC, Gonzalez FJ, et al: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics1994;4:39—42.
69.
Kidd RS, Straughn AB, Meyer MC, et al: Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics1999;9:71—80.
70.
Dickmann LJ, Rettie AE, Kneller MB, et al: Identification and functional characterization of a new CYP2C9 variant (CYP2C9* 5) expressed among African Americans. Mol Pharmacol2001;60: 382—387.
71.
De Morais SM, Wilkinson GR, Blaisdell J., et al: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem1994;269:15419—15422.
72.
Ibeanu GC, Goldstein JA, Meyer U., et al: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther1998;286:1490—1495.
73.
De Morais SM, Wilkinson GR, Blaisdell J., et al: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism [in Japanese]. Mol Pharmacol1994; 46: 594—598.
74.
Ferguson RJ, De Morais SM, Benhamou S., et al: A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther1998;284:356—361.
75.
Xiao ZS, Goldstein JA, Xie HG, et al: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther1997; 281:604—609.
76.
Ibeanu GC, Blaisdell J., Ghanayem BI, et al: An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics1998;8: 129—135.
77.
Ibeanu GC, Blaisdell J., Ferguson RJ, et al: A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther1999;290:635—640.
78.
Hu Y., Oscarson M., Johansson I., et al: Genetic polymorphism of human CYP2E1: Characterization of two variant alleles. Mol Pharmacol1997;51:370—376.
79.
McCarver DG , Byun R., Hines RN, et al: A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol1998;152:276—281.
80.
Kuehl P., Zhang J., Lin Y., et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet2001;27:383—391.
81.
Hayes J., Strange R.: Glutathione-S-transferase polymorphisms and their biological consequences . Pharmacology2000;61:154—166.
Seidegard J. , Ekstrom G.: The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect1997;105:791—799.
84.
Evans D.: Glucuronosyltransferases, in Evans D (ed): Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics . Cambridge, Cambridge University Press, 1993, 306—316.
85.
Evans D.: Glutathione-S-transferase, in Evans D (ed): Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics . Cambridge, Cambridge University Press, 1993, 317—329.
86.
Farin FM, Omiecinski CJ: Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. J Toxicol Environ Health1993;40:317—335.
87.
de Waziers I., Cugnenc PH, Yang CS, et al: Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther1990;253:387—394.
88.
Hassett C., Aicher L., Sidhu JS, Omiecinski CJ: Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet1994;3:421—428.
89.
Omiecinski CJ, Hassett C., Hosagrahara V.: Epoxide hydrolase— polymorphism and role in toxicology. Toxicol Lett2000;112—113: 365—370.
90.
Fuhr U.: Induction of drug metabolising enzymes: Pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet2000;38:493—504.
91.
Goodwin B., Moore LB, Stoltz CM, et al: Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol2001;60:427—431.
92.
Quattrochi LC, Guzelian PS: Cyp3A regulation: From pharmacology to nuclear receptors. Drug Metab Dispos2001; 29: 615—622.
93.
Sueyoshi T. , Negishi M.: Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Ann Rev Pharmacol Toxicol2001;41:123—143.
94.
Claes L., Del-Favero J., Ceulemans B., et al: De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet2001;68:1327—1332.
95.
Escayg A., Heils A., MacDonald BT, et al: A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus— And prevalence of variants in patients with epilepsy. Am J Hum Genet2001;68:866—873.
96.
Wallace RH, Scheffer IE, Barnett S., et al: Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. Am J Hum Genet2001;68:859—865.
97.
Feucht M., Fuchs K., Pichlbauer E., et al: Possible association between childhood absence epilepsy and the gene encoding GABRB3. Biol Psychiatry1999;46:997—1002.
98.
Goodwin H., Curran N., Chioza B., et al: No association found between polymorphisms in genes encoding mGluR7 and mGluR8 and idiopathic generalised epilepsy in a case control study . Epilepsy Res2000;39:27—31.
99.
Sander T., Hildmann T., Kretz R., et al: Allelic association of juvenile absence epilepsy with a GluR5 kainate receptor gene (GRIK1) polymorphism. Am J Med Genet1997;74:416—421.
100.
Evans D.: Antibiotic deafness and other topics, in Evans D (ed): Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics. Cambridge, Cambridge University Press, 1993, 574—584.
101.
Schinkel AH : P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev1999;36:179—194.
102.
Tishler DM , Weinberg KI, Hinton DR, et al: MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia1995;36:1—6.
103.
Lazarowski A., Sevlever G., Taratuto A., et al: Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol1999; 21: 731—734.
104.
Cascorbi I. , Gerloff T., Johne A., et al: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther2001;69:169—174.
105.
Hoffmeyer S., Burk O., von Richter O., et al: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A2000;97: 3473—3478.
